Engler C, Sander B, Villumsen J, Lund-Andersen H
Department of Ophthalmology, Gentofte Hospital, University of Copenhagen, Denmark.
Br J Ophthalmol. 1994 Oct;78(10):749-53. doi: 10.1136/bjo.78.10.749.
The first double masked placebo controlled trial of interferon alfa-2a for the treatment of overt choroidal neovascular membranes is presented. A total of 43 consecutive patients were randomised to double masked treatment with either interferon alfa-2a, 3 million IU subcutaneously three times a week or matching placebo, for a period of 8 weeks. End of study changes from baseline in distance and near visual acuity, macular visual field, contrast sensitivity, and macular morphology (fluorescein angiography) were assessed. The between group difference in distance visual acuity, the primary efficacy variable, was significant in favour of interferon alfa-2a (p = 0.023). Fluorescein angiograms, macular visual fields, and near vision all showed a trend in favour of interferon alfa-2a. It was concluded that, at the dosage used in this study, interferon alfa-2a is a reasonably well tolerated and apparently effective short term treatment of subfoveal and juxtafoveal choroidal neovascularisations.
首次关于α-2a干扰素治疗显性脉络膜新生血管膜的双盲安慰剂对照试验公布。共有43例连续患者被随机分为双盲治疗组，一组接受α-2a干扰素，每周皮下注射300万国际单位，共三次，另一组接受匹配的安慰剂，为期8周。评估了研究结束时与基线相比在远视力、近视力、黄斑视野、对比敏感度和黄斑形态（荧光素血管造影）方面的变化。作为主要疗效变量的远视力组间差异显著，α-2a干扰素组占优（p = 0.023）。荧光素血管造影、黄斑视野和近视力均显示出α-2a干扰素组占优的趋势。得出的结论是，在本研究使用的剂量下，α-2a干扰素是一种耐受性相当良好且在短期内对黄斑下和黄斑旁脉络膜新生血管形成明显有效的治疗方法。
